+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data



Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data



European Journal of Drug Metabolism and Pharmacokinetics 33(4): 247-252



Allometric principles have been applied to scale and predict human pharmacokinetic parameters of irbesartan, an important AT1 receptor antagonist. The preclinical data gathered from rats, macaques (monkeys) and dogs were used in the allometric analysis. The use of these species was rationalized because preclinical models based on these species have been used in the evaluation pharmacodynamic activity of irbesartan. The human parameter values for clearance (CL/F), volume of distribution (V/F), and elimination rate constant (Kel) were scaled using simple allometry (CL/F, V/F and Kel) or with correction factors (CL/F). The predictions of both CL/F and elimination half life (T1/2) (using Kel) for irbesartan appeared to be in close proximity to the respective human reported values (CL/F: predicted=18 L/h, observed=22.2 L/h; T1/2: predicted = 9 h; observed = 10-20 h); while, V/F value was marginally over predicted by 1.75-fold using simple allometry (predicted = 456 L; observed = 260 L). The present work presents an opportunity for prospective allometric scaling for the compounds belonging to this important therapeutic class.

(PDF emailed within 1 workday: $29.90)

Accession: 051607980

Download citation: RISBibTeXText

PMID: 19230599



Related references

Prediction of human pharmacokinetic parameters using animal data and principles of allometry. A case using bicifadine, a non-narcotic analgesic, as an example. Arzneimittel-Forschung 59(12): 625-630, 2010

Feasibility of developing a neural network for prediction of human pharmacokinetic parameters from animal data. Pharmaceutical Research 10(3): 466-469, 1993

Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. Journal of Hypertension. Supplement 15(7): S15-S20, 1998

Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. European Journal of Drug Metabolism and Pharmacokinetics 36(2): 87-93, 2011

Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan. Journal of Separation Science 32(14): 2353-2358, 2009

Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data. Journal of Pharmaceutical Sciences 74(10): 1097-1099, 1985

Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. Journal of Clinical Pharmacology 53(2): 178-191, 2013

Application of pharmacokinetic principles in the extrapolation of animal data to humans. Clinical Toxicology 9(5): 709-722, 1976

The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. American Journal of Hypertension 10(12 Pt 2): 311s-317s, 1998

The new angiotensin II receptor antagonist, irbesartan. Pharmacokinetic and pharmacodynamic considerations. American Journal of Hypertension 10(12 PART 2): 311S-317S, 1997

Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. Journal of Clinical Pharmacology 53(2): 167-177, 2013

Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 34(6): 571-579, 2004

Prediction of human bioavailability from human oral administration data and animal pharmacokinetic data without data from intravenous administration of drugs in humans. Pharmaceutical Research 26(8): 1881-1889, 2009

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. Journal of Pharmacology and Experimental Therapeutics 283(1): 46-58, 1997